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ABSTRACT
Primary cerebral malignant melanoma accounts for 1% of all melanomas and for 0.7% of all primary
tumours of the central nervous system (CNS). We report an incidentally found primary malignant melanoma
in the right temporal lobe of a 76-year-old woman with an Ota nevus on her right eyelid and sclera. The
lesion was initially characterised by slow growth, followed by tumoural bleeding and wide leptomeningeal
dissemination. Magnetic resonance imaging (MRI) during brain checkup demonstrated an 8-mm mass in
the right uncus with high intensity on T1-weighted images. The mass grew slowly over the next two years,
but asymptomatic tumoural haemorrhage eventually developed. The patient underwent tumour removal via
right frontotemporal craniotomy. Extensive subarachnoid dissemination from the right temporal tumour
was found; the pathologic diagnosis was malignant melanoma. Despite adjuvant therapy comprising whole-
brain radiation and nivolumab, the patient died of severe leptomeningeal dissemination at 4.5 months after
the operation (33 months after the initial MRI study). Our literature review found 46 cases of primary CNS
malignant melanoma, predominantly in middle-aged to elderly individuals. The most frequent symptom was
headache, followed by visual disturbance, nausea/vomiting, and hemiparesis. Only one other case of primary
cerebral malignant melanoma had been found incidentally; 11 previously reported patients manifested con-
genital nevi (Ota nevus, n = 5; other nevi, n = 6). Six patients suffered tumoural haemorrhage, 4 experienced
leptomeningeal dissemination, and 5 developed extracranial metastases. The median survival time of the
patients was 31 months.
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Primary malignant melanoma of the central nervous
system (CNS) is a rare tumour. It arises from leptome-
ningeal melanocytes and accounts for 1% of all melano-
mas and 0.7% of all primary CNS tumors8,26). Most
patients present with increased intracranial pressure,
neurological deficits, and seizures33), but asymptomatic
cases also rarely occur36).
We report an incidentally found primary malignant
melanoma in the right temporal lobe of a woman previ-
ously treated for an Ota nevus. The lesion was initially
characterised by slow growth, followed by tumoural
bleeding and wide leptomeningeal dissemination. We
also present a literature review of patients with primary
CNS malignant melanoma.
CASE REPORT
A 76-year-old woman had received YAG laser treat-
ment 10 years earlier for an Ota nevus on her right eyelid
and sclera (Figure 1). Without particular symptoms, she
subsequently underwent a brain checkup. The examina-
tion revealed a single, 8-mm diameter round mass in the
right uncus. On magnetic resonance imaging (MRI), the
lesion was hyperintense on T1- (Figure 2A) and hypoin-
tense on T2-weighted images (T1WI, T2WI). Follow-up
MRI performed at a local clinic 11 months after the ini-
tial study revealed slight enlargement of the lesion (Fig-
ure 2B), suggesting cavernous angioma. Subsequent
follow-up showed further growth (Figures 2C, D). The
tumour diameter was 20 mm (Figures 3A, B) 24 months
after the initial brain checkup. It had very low signal
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intensity on T2WI scans (Figure 3C) and strongly
enhanced with gadolinium (Figure 3D). As these findings
indicated an aggressive tumour, the patient was referred
to us for further evaluation and treatment. Her admis-
sion was postponed owing to the lack of symptoms.
At the time of admission to our hospital 28 months
Figure 1 Ota nevus on right eyelid (arrows) and sclera (ar-
row head)
after the initial MRI scan, the patient was symptom-free.
Computed tomography (CT) scan revealed haematoma
surrounding the tumour (Figure 4), and the patient
underwent right anterior temporal craniotomy. The
brain surface was covered by innumerable black spots
suggestive of disseminated malignant melanoma (Figure
5A). The temporal lobe tumour exposed by the trans-
Sylvian approach was pitch-black with interlacing hae-
morrhage (Figure 5B). The main mass was removed
completely without sequelae.
Haematoxylin-eosin (HE) staining of a surgical speci-
men showed sheet-like proliferation of heavily pig-
mented cells with significant pleomorphism, nuclear
enlargement, increased nuclear chromatin, and nucleo-
lar prominence (Figure 6A). Immunohistochemically,
the cells were positive for HMB-45 (Figure 6B) and
melan-A (Figure 6C). The MIB 1 index was 17.7% (Fig-
ure 6D). These findings were compatible with malignant
melanoma. The cells were negative for BRAF mutation.
The patient’s postoperative course was uneventful. She
subsequently underwent dermatological assessment,
funduscopy, whole-body CT, and whole-body FDG-
positron emission tomography (FDG-PET). None of
these studies revealed evidence of melanoma or malig-
nancy in other parts of the body.
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Figure 2 Magnetic resonance imaging (MRI) studies performed before admission to our hospital. (A) September 2014. Axial T1-
weighted imaging (T1WI) revealed an 8-mm diameter high-intensity mass (arrow) in the right uncus. Follow-up T1WI demonstrat-
ed gradual enlargement of the lesion (B: August 2015, C: February 2016, D: August 2016).
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Despite adjuvant therapy comprising whole-brain
radiation (40 Gy in 20 fractions) and an anti-PD-1 inhib-
itor (5 courses of 160 mg of nivolumab at 3-week inter-
vals), the patient gradually lost awareness, and she
became delirious by the end of the 4th month postopera-
tive. MRI showed no recurrence of the right temporal
tumour, but widespread dissemination in both the
supra- and infratentorial subarachnoid space was
observed (Figures 7A–D). The patient was transferred to
a nursing home where she died at 4.5 months after the
operation, i.e., 33 months after the initial MRI study.
In addition to our patient, our literature review found
45 previous patients with primary CNS malignant mela-
noma (Tables 1A, B)2–5,7–11,13–19,21–25,27–32,35–38).
A B
C D
Figure 3 MRI study obtained in September 2016 (24 months after first study). T1WI shows hyperintense mass at right uncus.
Mass was 20 mm in maximum diameter (A: axial scan, B: sagittal scan), very low intensity on T2WI scans (C), and strongly en-
hanced with gadolinium (D).
A B
Figure 4 Preoperative computed tomography (CT) images obtained in January 2017. Axial CT shows a round isodense lesion in
right uncus surrounded by thin haematoma (A, B) (arrows).
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DISCUSSION
Primary CNS malignant melanoma is very rare; the
reported incidence is 0.005 cases per 16) individuals26). In
the present case, the lesion was incidentally found in a
patient who harboured an Ota nevus on the side ipsilat-
eral to the lesion; it disseminated widely over the course
of two years.
On MRI scans, CNS melanoma is typically depicted as
a round mass hyperintense on T1WI and hypointense on
T2WI scans owing to melanin deposits in neoplastic
cells. However, these characteristics depend on the con-
centration of melanin; when fewer than 10% of neoplas-
tic cells are melanin-positive, T1WI may reveal
hypointensity and T2WI hyperintensity2,35).
T1WI revealed hyperintensity in our patient. However,
as tumour growth was very slow, a diagnosis of caver-
nous angioma was made in an outside institution, and
her referral to us was delayed. Spontaneous haemor-
T
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Figure 5 Intraoperative observations. Brain surface was covered by abundant black spots suggestive of subarachnoid dissemina-
tion of melanoma (A). Exposure of uncal tumour through Sylvian fissure revealed pitch-black surface interlaced with thin haemor-
rhage (B). F: Frontal lobe, S: Sylvian fissure, T: temporal lobe, *: tumour, D: dura mater
A B
C D
Figure 6 Histopathology of surgical specimen. Haematoxylin-eosin (HE) staining showed diffuse proliferation of compact neo-
plastic cells containing iron deposits, significant nuclear pleomorphism, and conspicuous nucleoli (A). Neoplastic cells were strong-
ly positive for HMB-45 (B) and melan-A (C). MIB-1 index was 17.7% (D).
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rhage is frequently reported in patients harbouring mela-
noma because the tumour is rich in blood vessels and
can easily invade the vessels of the meninges24).
Depending on the time course after intratumoural hae-
matoma, intracerebral cavernous angioma may be also
hyperintense on T1WI scans. However, on MRI scans,
cavernous angiomas tend to display different levels of
intensity among multiple cysts, yielding a characteristic
“popcorn” or “raspberry” appearance surrounded by a
rim of signal loss due to haemosiderin deposits12).
In patients with malignant melanoma, leptomeningeal
infiltration by malignant cells is common. The condition
is recognized as widespread enhancement of the subar-
achnoid space and sulci21) and tends to appear in the
advanced stage of the disease. In our patient, however, it
appeared at the asymptomatic stage.
Primary CNS malignant melanoma is usually aggres-
sive, and approximately 50% of patients previously
reported to have the disease died within 31 months. Ini-
tially the tumour in our case grew very slowly. Some
patients manifest distant metastasis after a quite lengthy
interval following the resection of a malignant mela-
noma. This dormancy may reflect a lack of sufficient
tumour vascularity and similar rates of cell proliferation
and apoptosis6).
The patient in this case study harboured Ota nevus
(oculodermal melanocytosis) around the right eye. Previ-
ously, there were reports of 4 patients with Ota nevus; in
3 of these, as in our patient, the lesion was ipsilateral to
the intracranial lesion. Ota nevi consist of an extensive
patch-like area of dermal melanocytic hyperpigmenta-
tion that usually involves the distribution of the first and
second branches of the trigeminal nerve. Their embryo-
logic origin is similar to that of intracranial melanocytic
lesions. Melanoblasts arise in the neural crest and differ-
entiate into melanocytes that migrate into the skin, ocu-
lar structure, and pia mater predominantly on the brain
stem and upper cervical spine. Mismigration and neo-
plastic transformation of these melanocytes may lead to
Ota nevus and CNS melanoma11).
In the absence of standardised treatment for malig-
nant CNS melanoma, first-line treatment consists of
maximal safe removal followed by external beam radia-
tion (40 to 70 Gy) and chemotherapy26). Methotrexate,
dacarbazine, vincristine, temozolomide, and interferon
are major chemotherapeutic agents. Anti-PD-1 inhibi-
tors have been used to address malignant melanoma, but
their effectiveness in patients with malignant CNS mela-
noma remains to be established20). After the discovery of
the BRAF mutation in malignant melanoma, anti-BRAF
A B
DC
Figure 7 Follow-up magnetic resonance imaging (MRI) study performed 4 months after surgery. Gadolinium-enhanced scans
showed strong enhancement of subarachnoid space suggesting thick and widespread dissemination (A: axial, B: coronal, C: sagittal
image). No local recurrence was seen (A and D: T2 axial)
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agents have been used for malignant melanoma in skin
regions. Our literature review found only one report on
the use of a BRAF inhibitor in a patient with primary
CNS melanoma arising in the pineal gland; however, this
treatment was not successful16). Others1,34) have sug-
gested the usefulness of combinations of immunocheck-
point inhibitors, BRAF/MEK inhibitors, and stereotactic
radiosurgery for CNS metastases from melanoma. These
combinations may be also useful to treat primary CNS
malignant melanoma.
According to our literature review, the prognosis of
patients with CNS malignant melanoma varied widely;
10 of 27 patients died within 12 months and 4 survived
longer than 5 years, including one patient who died 17
years after the initial surgery23). Kaplan-Meier analysis of
the overall survival is shown in Figure 8; the median sur-
vival time was 31 months. However, once the neoplastic
cells spread to the leptomeninges the prognosis is omi-
nous and the survival tends to be 10 weeks33).
CONCLUSION
The present report represents the second reported
case of an incidentally found primary CNS malignant
melanoma, whose slow growth resulted in a misdiagno-
sis of cavernous angioma. We suspect that the number of
patients with asymptomatic malignant CNS melanoma
will rise with the number of MRI studies performed in
“healthy” individuals and patients with minor symptoms.
Education of local medical care providers regarding the
radiologic features of malignant melanoma may result in
early diagnosis. To improve outcomes, an effective treat-
ment strategy for primary CNS malignant melanoma is
needed.
Table 1A Summary of 46 patients with primary malignant CNS melanoma
Variable Number of patients
Age
median, mean ± SD 49, 47.0 ± 18.3
<40 17 (37.0%)
40–60 16 (34.8%)
>60 13 (28.3%)
Sex
male 24 (52.2%)
female 22 (47.8%)
Tumor site SD (double count was allowed)
frontal lobe 12
parietal lobe 10
temporal lobe 9
occipital lobe 4
skull base 5
cerebellopontine angle 4
pineal region 4
cerebral sulci 3
dura mater 2
pons 1
Symptoms (double count was allowed)
headache 27
visual disturbance 10
nausea/vomiting 9
hemiparesis 8
seizure 7
hearing disturbance 5
numbness 5
dizziness 5
ataxia 5
vertigo 3
aphasia 3
none 2
Other skin lesions
Ota nevus 5
uveal melanoma 1
hairy navus (leg) 1
congenital melanocytic nevus (trunk) 4
SD (standard deviation)
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Table 1B Summary of 46 patients with primary malignant CNS melanoma
Variable Number of patients
Image diagnosis
T1 high 36
T2 low 16
strong enhancement 27
tumoral hemorrhage 7
meningeal dissemination 8
Extent of surgical removal
total excision 28
subtotal excision 8
unknown 3
not performed 6
Adjuvant treatment
radiotherapy 31
chemotherapy 18
immunotherapy 3
Survival
median survival 31 months
<1 years 10
1–5 years 5
>5 years 4
T1 high: high intensity on T1 weighted magnetic resonance imaging
T2 low: low intensity on T2 weighted magnetic resonance imaging
Figure 8 Kaplan-Meier analysis of overall survival of 45 previously reported cases and our patient with primary CNS malignant
melanoma. Median survival was 31 months.
Incidentally found primary mCNS melanoma 27
REFERENCES
 1. Ahmed, K.A., Abuodeh,Y.A., Echevarria, M.I., Amington,
J.A., Stallworth, D.G., Hogue, C., et al. 2016. Clinical
outcomes of melanoma brain metastases treated with
stereotactic radiosurgery and anti-PD-1 therapy, anti-
CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor,
or conventional chemotherapy. Ann. Oncol. 27: 2288–
2294.
 2. Arantes, M., Ferreira, A., Romão, H., Meireles, P.,
Garcia, R., Honavar, M., et al. 2011. Primary pineal
malignant melanoma: Case report and literature review.
Clin. Neurol. Neurosurg. 113: 59–64.
 3. Arobelitze, S., Sadiek, H.F., Tripuraneni, R., Daw, H.,
Spiro, T. and Haddad, A. 2017. Primary Leptomeningeal
Melanoma in Patient with Multiple Congenital
Melanocytic Nevi Treated with Ipilimumab. J. Oncol.
Pract. 1: 211–212.
 4. Azar, M., Kazemi, F., Bahrami, E., Hejazian, E.,
Fereshtehnejad, S.M., Ahmadi, A., et al. 2010. Meningeal
melanomas associated with transforming Ota nevus to
malignant melanoma: A case report. Brain 24: 163–168.
 5. Balakrishnan, R., Porag, R., Asif, D.S., Satter, A.M.R.,
Taufiq, M. and Gaddam, S.S.K. 2015. Primary
intracranial melanoma with early leptomeningeal spread:
A case report and treatment options available. Case Rep.
Oncol. Med. Volume 2015, Article ID 293802, 7 pages.
http://dx.doi.org/10.1155/2015/293802
 6. Barnhill, R.L., Piepkorn, M.W., Cochran, A.J., Flynn, E.,
Karaoli, T. and Folkman, J. 1998. Tumor vascularity,
proliferation, and apoptosis in human melanoma
micrometastases and macrometastases. Arch. Dermatol.
134: 991–994.
 7. Bhandari, L., Alapatt, J., Govindan, A. and Sreekumar, T.
2012. Primary cerebellopontine angle melanoma: A case
report and review. Turk. Neurosurg. 22: 469–474.
 8. Crasto, G., Soffietti, R., Bradac, G. and Boldorini, R.
2001. Primitive cerebral melanoma: Case report and
review of the literature. Surg. Neurol. 55: 163–168.
 9. Dinesh, SM., Suneetha, B. and Sen, A. 2013. A rare case
of primary malignant melanoma of clivus with extensive
skeletal metastasis demonstrated on 18F-FDG PET/CT.
Indian J. Nucl. Med. 28: 234–236.
10. Freudenstein, D., Wagner, A., Bornemann, A.,
Ernemann, U., Bauer, T. and Duffner, F. 2004. Primary
melanocytic lesions of the CNS: Report of five cases.
Zentralbl. Neurchir. 65: 146–153.
11. Guthikonda, B., Ahmed, O., Buckleair, L.J., Goodman,
J.C., Powell, S.Z. and Yoshor, D. 2015. Primary CNS
malignant melanoma associated with a contralateral
nevus of Ota in an African-American female: Unique
Case Report. Cancer Clin. Oncol. 4: 39–46.
12. Hegde, A.N., Mohan, S. and Lim, C.C.T. 2012. CNS
cavernous haemangioma: “Popcorn” in the brain and
spinal cord. Clin. Radiol. 67: 380–388.
13. Hirota, K., Yoshimura, C., Kubo, O. and Kasuya, H. 2017.
Primary intracranial malignant melanoma with
extracranial metastasis. J. Korean Neurosurg. Soc. 60:
98–101.
14. Hsieh, Y.Y., Yang, S.T., Li, W.H., Hu, C.J. and Wang, L.S.
2015. Primary leptomeningeal melanoma mimicking
meningitis: A case report and literature review. J. Clin.
Oncol. 32: 57–61.
15. Iizuka, H., Nakamura, T. and Kurauchi, M. 1990.
Primary intracranial melanoma. Neurol. Med. Chir. 30:
698–702.
16. Jetschke, K., Viehweger, H., Freesmeyer, M., Warnke,
JP. and Mawrin, C. 2015. Primary pineal malignant
melanoma with B-Raf V600E mutation: A case report
and brief review of the literature. Acta Neurochir.
(Wien). 157: 1267–1270.
17. Lanka, K., Kumari, NSM., Sireesha, A. and Kumar, OS.
2015. A rare case of primary malignant melanoma in
CNS. Int. Surg. J. 2: 95–97.
18. Lee, C.J., Rhee, D.Y., Heo, W. and Park, H.S. 2004.
Primary leptomeningeal malignant melanoma. J. Korean
Neurosurg. Soc. 36: 425–427.
19. Lee, P.H., Wang, L.C. and Lee, E.J. 2016. Primary
intracranial melanoma. J. Cancer Res. Pract. 4: 23–26.
20. Liniker, E., Menzies, A.M., Kong, B.Y., Cooper, A.,
Ramanujam, S., Lo, S., et al. 2016. Activity and safety of
radiotherapy with anti-PD-1 drug therapy in patients
with metastatic melanoma. Oncoimmunol. 5: 1–7.
21. Ma, Y., Gui, Q. and Lang, S. 2015. Intracranial malignant
melanoma: A report of 7 cases. Oncol. Lett. 10: 2171–
2175.
22. Nakagawa, H., Hayakawa, T., Niiyama, K., Nii, Y.,
Yoshimine, T. and Mori, S. 1989. Long-term survival
after removal of primary intracranial malignant
melanoma. Acta Neurochir. 101: 81–88.
23. Önal, C., Özyiǧit, G., Akyürek, S., Selek, U., Özyar, E. and
Atahan, IL. 2006. Primary intracranial solitary
melanoma: A rare case with long survival. Turk. J.
Cancer 36: 185–187.
24. Pan, Z., Yang, G., Wang, Y., Yuan, T., Gao, Y. and Dong,
L. 2014. Leptomeningeal metastases from a primary
central nervous system melanoma: A case report and
literature review. World J. Surg. Oncol. 12: 1–5.
25. Ponni, A., Jagannatha, A., Gururajachar, J., Harjani, R.,
Koushik, K., Subramanian, N., et al. 2012. Primary
cerebellopontine angle melanoma: A case report and
review. Turk. Neurosurg. 22: 469–474.
26. Quillo-Olvera, J., Uribe-Olalde, JS., Alcántara-Gómez,
LA., Rejón-Pérez, JD. and Palomera-Gómez, HG. 2015.
Primary malignant melanoma of the central nervous
system: A diagnostic challenge. Cirugía y Cirujanos
(English Ed) 83: 129–134.
27. Said, S., Alkhateeb, H., Cooper, C.J., Galvis, J.M., Fang,
H., Hernandez, G.T., et al. 2014. Primary central nervous
system amelanotic melanoma in a Hispanic male: Case
report. Pol. J. Radiol. 79: 199–202.
28. Shah, I., Imran, M., Akram, R., Rafat, S., Zia, K. and
Emaduddin, M. 2013. Primary intracranial malignant
melanoma. J. Coll. Physicians. Surg. Pak. 23: 157–159.
29. Shakya, A. and Huang, J. 2015. Neurocutaneous
melanosis presented with giant congenital melanocytic
nevi and primary intracranial melanoma. J. Kathmandu
Med. Coll. 4: 29–33.
30. Shinsato, Y., Hanada, T., Kisanuki, T., Yonezawa, H.,
Yunoue, S., Yoshioka, T., et al. 2012. Primary malignant
melanoma in the pineal region treated without
chemotherapy. Surg. Neurol. Int. 3: 123.
31. Somers, K., Almast, J., Biemiller, R., Silberstein, H.,
Johnson, M. and Mohile, N. 2017. Diagnosis of primary
CNS melanoma. J. Clin. Oncol. 31: 17–19.
32. Suranagi, V.V., Maste, P. and Malur, P.R. 2015. Primary
intracranial malignant melanoma: A rare case with
review of literature. Asian J. Neurosurg. 10: 39–41.
33. Tang, K., Kong, X., Mao, G., Qiu, M., Zhu, H., Zohou, L.,
et al. 2017. Primary cerebral malignant melanoma.
Medicine 96: 1–6.4.
34. Trino, E., Mantovani, C., Badellino, S., Ricardi, U. and
Filippi, A.R. 2017. Radiosurgery/stereotactic
radiotherapy in combination with immunotherapy and
28 N. Tanoue et al
targeted agents for melanoma brain metastases. Expert
Rev. Anticancer Ther. 17: 347–356.
35. Wadasadawala, T., Trivedi, S., Gupta, T., Epari, S. and
Jalali, R. 2010. The diagnostic dilemma of primary
central nervous system melanoma. J. Clin. Neurosci. 17:
1014–1017.
36. Wang, J., Guo, Z.Z., Wang, Y.J., Zhang, S.G. and Xing,
D.G. 2014. Microsurgery for the treatment of primary
malignant intracranial melanoma: A surgical series and
literature review. Eur. J. Surg. Oncol. 40: 1062–1071.
37. Xie, Z.Y., Hsieh, K.L.C., Tsang, Y.M., Cheung, W.K. and
Hsieh, C.H. 2014. Primary leptomeningeal melanoma. J.
Clin. Neurosci. 21: 1051–1052.
38. Yuen, M.H., Kwok, N.F., Chiu, H.M. and Ho, L.C. 2016.
Rare tumour mimicking meninigioma: A case of primary
intracranial amelanotic malignant melanoma with
negative staining of S100 and HMB-45. Surg. Pract. 20:
171–174.
Incidentally found primary mCNS melanoma 29
